Prolongation of Survival of an Allograft by Inhibiting Complement Activity
AssigneeAlexion Pharmaceuticals, Inc.
InventorsRussell P. Rother, Hao Wang, Zheng Zhong
Life of this patent
Estimating the term…
Abstract
Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allograft recipient an inhibitor of complement activity together with one or more immunosuppressants and/or immunosuppressive methods. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.
Claims86
A method of prolonging survival of a kidney allograft in a recipient mammal, said method comprising administering to said mammal a) a drug which inhibits complement activity and b) at least one immunosuppressive therapy wherein said therapy is selected from i) at least one immunosuppressive drug or ii) an immunomodulatory treatment.
(canceled)
24-26. (canceled)
(canceled)
45-88. (canceled)
A method of prolonging survival of an allograft in a recipient mammal, said method comprising administering to said mammal a) a drug which inhibits complement activity and b) at least one immunosuppressive therapy wherein said therapy is selected from i) at least one immunosuppressive drug comprising LF15-0195 or ii) an immunomodulatory treatment.
(canceled)
110-112. (canceled)
(canceled)
131-172. (canceled)
A pharmaceutical package comprising a drug that inhibits complement activity and at least one immunosuppressive drug, wherein said drug that inhibits complement activity and said immunosuppressive drug are formulated for chronic administration, wherein at least one immunosuppressive drug comprises LF15-0195.
174-188. (canceled)
Dependencies are inferred from the claim text.